CanSense is an accurate, rapid, non-invasive, blood diagnostic for the early detection of cancer.
CanSense has raised $1.8M in total funding. The most recent round was Seed. The last funding was announced in March 2023.
CanSense's investors include Development Bank of Wales, Mercia Fund Managers, National Institute for Health and Care Research, Nonacus.
CanSense is headquartered in Swansea, United Kingdom.
CanSense is an accurate, rapid, non-invasive, blood diagnostic for the early detection of cancer.
CanSense is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"CanSense — Funding & Investors." VCBacked, March 8, 2023, https://www.vcbacked.co/company/cansense. Accessed August 15, 2026.
VCBacked. (2023). CanSense — Funding & Investors. Retrieved August 15, 2026, from https://www.vcbacked.co/company/cansense
{{cite web |title=CanSense — Funding & Investors |url=https://www.vcbacked.co/company/cansense |website=VCBacked |access-date=August 15, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated